- Conditions
- Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injury, Central Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male, Spinal Cord Trauma, Injuries, Spinal Cord, Walking, Difficulty, Gait Disorders, Neurologic, Locomotion Disorder, Neurologic, Wounds and Injuries, Nervous System Diseases, Testosterone Deficiency, Androgen Deficiency, Hormone Deficiency
- Interventions
- Testosterone Enanthate, Locomotor Training
- Drug · Behavioral
- Lead sponsor
- North Florida Foundation for Research and Education
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Jacksonville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 34
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Advanced Solid Tumors, Advanced Breast Cancer
- Interventions
- ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination with fulvestrant
- Drug
- Lead sponsor
- Ensem Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 10
- States / cities
- Newport Beach, California • San Francisco, California • New Haven, Connecticut + 6 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- FT-7051
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Chicago, Illinois + 5 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- lapatinib
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 3
- States / cities
- Kansas City, Kansas • Topeka, Kansas • Kansas City, Missouri
- Conditions
- Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
- Interventions
- Abemaciclib, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 925 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 63
- States / cities
- Prescott, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 57 more
- Conditions
- Proctitis, Proctosigmoiditis
- Interventions
- Budesonide, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 60 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Tirzepatide, Dulaglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 13,299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Concord, California • Covina, California + 106 more
- Conditions
- Proctitis, Proctosigmoiditis
- Interventions
- Budesonide Foam
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injuries, Central Nervous System Diseases, Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male
- Interventions
- Testosterone Enanthate, Finasteride, Placebo injection, Placebo pill
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Tampa, Florida
- Conditions
- Controlled Ovarian Stimulation
- Interventions
- Not listed
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 31 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2014
- U.S. locations
- 1
- States / cities
- Lutherville, Maryland
- Conditions
- Breast Cancer, Solid Tumors, Adult
- Interventions
- STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 880 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 28
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
- Conditions
- Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
- Interventions
- Antiandrogen Therapy, Laboratory Biomarker Analysis, Multitargeted Tyrosine Kinase Inhibitor PLX3397, Radiation Therapy
- Drug · Other · Radiation
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Petoskey, Michigan
- Conditions
- Breast Neoplasms, Breast Diseases
- Interventions
- Anastrozole, Palbociclib, Trastuzumab, Pertuzumab
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 5
- States / cities
- New York, New York
- Conditions
- Infertility
- Interventions
- Oral contraceptive pill and microdose lupron, E2 patch/antagonist
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- ER-Positive HER2-Negative Breast Cancer
- Interventions
- AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 64
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more
- Conditions
- Granulomatosis With Polyangiitis, Wegener Granulomatosis, Vasculitis
- Interventions
- 5 mg prednisone, 0 mg prednisone
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Obesity, Overweight
- Interventions
- Orforglipron, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Pelham, Alabama • Santa Ana, California + 21 more
- Conditions
- Proctitis, Proctosigmoiditis
- Interventions
- Budesonide, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 62
- States / cities
- Dothan, Alabama • Mesa, Arizona • Tucson, Arizona + 59 more
- Conditions
- Hot Flashes
- Interventions
- Estradiol transdermal one 90 μL spray, Estradiol transdermal spray, two 90 μL sprays, Estradiol transdermal three 90 μL sprays, Placebo transdermal two 90 μL sprays, Placebo transdermal three 90 μL sprays, Placebo transdermal one 90 μL spray
- Drug
- Lead sponsor
- Lumara Health, Inc.
- Industry
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 454 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Oro Valley, Arizona + 37 more
- Conditions
- Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension, Lung Diseases, Tamoxifen, Estrogen Receptor Antagonist, Hormone Antagonists, Estrogens
- Interventions
- Tamoxifen, Placebo Oral Tablet
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Elderly
- Interventions
- GHRH
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Boston, Massachusetts
- Conditions
- Hormone Deficiency, Aging
- Interventions
- Growth Hormone Releasing Hormone (GHRH )
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- ER-Positive HER2-Negative Breast Cancer
- Interventions
- AZD9833, Anastrozole, Anastrozole placebo, AZD9833 placebo, Palbociclib, Luteinizing hormone-releasing hormone (LHRH) agonist
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 30
- States / cities
- Mobile, Alabama • Springdale, Arkansas • Harbor City, California + 25 more
- Conditions
- Hypogonadism
- Interventions
- TSX-002
- Drug
- Lead sponsor
- TesoRx Pharma, LLC
- Industry
- Eligibility
- 18 Years to 70 Years · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- San Diego, California